Agomab Therapeutics NV announced that its management team will participate in several key healthcare and investor conferences in 2026, including ATS International, H.C. Wainwright BioConnect, RBC Capital Markets, JPM European Healthcare Symposium, BIO International Convention, and Leerink Partners Therapeutics Forum. The company will present data on AGMB-447, an inhaled lung-restricted inhibitor for idiopathic pulmonary fibrosis, highlighting its strong anti-fibrotic activity in preclinical and healthy subjects. These events provide Agomab opportunities to showcase its progress in developing novel therapies targeting fibro-inflammatory diseases with high unmet medical needs. Investors and industry participants can expect updates on Agomab’s clinical advancements and strategic outlook throughout the year.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum (ETH) has outperformed Bitcoin (BTC) in Q3, driven by a rally sparked by a softer CPI report and strong on-chain metrics. The recent surge pushed ETH above $1,900, triggering significant liquidations in futures positions. However, ETH now fa...
Solana's number of wallets holding tokenized real-world assets (RWAs) has exceeded 300,000, surpassing Ethereum's roughly 200,000 holders. While Solana's RWA value doubled in 2026 to $3.45 billion, Ethereum still leads with $16.3 billion in tokenized...
Baidu's board has approved a plan to convert to a dual-primary listing on the Hong Kong Stock Exchange's Main Board, alongside its existing Nasdaq listing. This move aims to enhance the liquidity of Baidu's shares, broaden its investor base, and prov...
